Nycomed and Almirall enter into co-branding agreement
A co-branding agreement has been reached between Nycomed and Almirall.
Business negotiations have resulted in Swiss medical specialist Nycomed teaming up with international medical firm Almirall.
The pair will join forces in a co-branding agreement for the commercialisation of pulmonary disease treatment Roflumilast in Spain.
Released in the European nation earlier in the year, the drug is an orally-administered, once-daily tablet that can help patients with chronic obstructive pulmonary disease (COPD).
Commenting on the agreement, Almirrall chief operating officer Luciano Conde expressed his approval of the move.
"It reinforces our portfolio with a first-in-class product and allows us to leverage our respiratory capabilities and expertise," he said.
Roflumilast has received marketing authorisation in the US, EU and a range of other countries.
In Europe, the drug is marketed under the brand name Daxas and clinical trials have showed its efficacy in improving lung function among patients with COPD.
Earlier in the month, the European Commission announced it would be opening a regulatory investigation into the proposed acquisition of MWM Holding by US building giant Caterpillar.